ArticleFrontiers in psychiatry2025
Case Report: Development of persistent genital arousal disorder due to a possible combination of medications.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Male Dromedary Reproductive Emergencies: Clinical Presentation, Diagnosis, Management and Prognosis.Animals : an open access journal from MDPI · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Persistent Genital Arousal Disorder (PGAD) is a rare and distressing condition characterized by persistent genital arousal in the absence of sexual desire. We present a unique case of a menopausal woman who developed PGAD after combined pharmacotherapy with trazodone, pregabalin, vaginal estriol, and depot medroxyprogesterone acetate (DMPA). Methods: The patient underwent comprehensive gynecological, neurological, and psychiatric evaluation. Menopausal status was confirmed by laboratory findings. A detailed pharmacological review was conducted to assess possible interactions affecting serotonergic, neuronal, and hormonal regulation. Results: PGAD symptoms emerged shortly after initiating the combination of these medications. Each drug has been individually associated with alterations in sexual function, but their concurrent use may have produced synergistic effects on neuroendocrine pathways. Gradual discontinuation of all medications resulted in complete remission of symptoms. Conclusion: This case supports the hypothesis that combined modulation of serotonergic, neuronal, and hormonal systems can trigger PGAD in predisposed menopausal women. Recognition of potential pharmacological interactions is crucial for diagnosis and management of PGAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.